Vimarsana
Biggest News Aggregation in the World

Foreign Issuer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Foreign Issuer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Foreign Issuer Today - Breaking & Trending Today

AstraZeneca : plans $1.5 billion manufacturing facility for antibody drug conjugates (ADCs) in Singapore - Form 6-K - Vimarsana News

AstraZeneca : plans $1.5 billion manufacturing facility for antibody drug conjugates (ADCs) in Singapore - Form 6-K

Published: May 20, 2024

A0072p FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or...

Source: marketscreener.com
Related Topics:
United StatesUnited KingdomPascal SoriotAdrian KempCommission File NumberCompany On Social Media AstrazenecaCompany SecretarySecurities ExchangeSingapore Economic Development BoardInvestor Relations TeamForeign IssuerSecurities Exchange ActFile NumberCrick AvenueRegulationst RuleCheong BoonChief Executive OfficerRare DiseasesSocial Media
Gilat Satellite : David McDonald will transition to the role of Vice Chairman of DataPath Board of Directors - Form 6-K - Vimarsana News

Gilat Satellite : David McDonald will transition to the role of Vice Chairman of DataPath Board of Directors - Form 6-K

Published: May 20, 2024

FORM 6 - K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

Source: marketscreener.com
Related Topics:
United StatesHagay KatzDavid McdonaldNicole RobinsonAdi SfadiaKiryat AryeDoron KerbelEhud HelftPetah TikvaSecurities ExchangeComtech TelecommunicationsGilat Satellite NetworksLiberty UniversityDatapath IncInternational SecurityHarvard University Kennedy School Of GovernmentCounsel CompanyGilat Satellite Networks LtdUs Department Of Defense DoSenior Executives In NationalExchange CommissionForeign IssuerSecurities Exchange ActKapayim StreetPrincipal Corporate Offices
AstraZeneca : SUPERNOVA Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19 in immunocompromised patient population - Form 6-K - Vimarsana News

AstraZeneca : SUPERNOVA Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19 in immunocompromised patient population - Form 6-K

Published: May 16, 2024

A6269o FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or...

Source: marketscreener.com
Related Topics:
United KingdomUnited StatesIskra ReicGhady HaidarAdrian KempMeerausw ImmunocompromiseHealth Database StudySecurities ExchangeCompany On Social Media AstrazenecaUniversity Of Pittsburgh Medical CenterLarge United States Commercial Insurance Health PlanForum Infect DisInvestor Relations TeamCommission File NumberCompany SecretaryLancet Regional HealthForeign IssuerSecurities Exchange ActFile NumberCrick AvenueRegulationst RulePittsburgh Medical CenterExecutive Vice PresidentImmune TherapiesRare Diseases
AstraZeneca : Calquence combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial - Form 6-K - Vimarsana News

AstraZeneca : Calquence combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial - Form 6-K

Published: May 2, 2024

A9173m FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or...

Source: marketscreener.com
Related Topics:
United KingdomUnited StatesAstrazeneca CalquenceSusan GalbraithAdrian KempLiud AcalabrutinibMichael WangMd Anderson Cancer CenterLymphoma Research FoundationCommission File NumberInvestor Relations TeamGracell Biotechnologies IncMantle Cell Lymphoma Program Of ExcellenceNational Organization For Rare DisordersCompany SecretaryHealth Database StudySecurities ExchangeCompany On Social Media AstrazenecaForeign IssuerSecurities Exchange ActFile NumberCrick AvenueRegulationst RulePuddin Clarke Endowed ProfessorMantle Cell Lymphoma Program
Gilat Satellite : RESOLUTIONS ADOPTED AT THE REGISTRANT'S ANNUAL GENERAL MEETING OF SHAREHOLDERS HELD ON MAY 2, 2024 - Form 6-K - Vimarsana News

Gilat Satellite : RESOLUTIONS ADOPTED AT THE REGISTRANT'S ANNUAL GENERAL MEETING OF SHAREHOLDERS HELD ON MAY 2, 2024 - Form 6-K

Published: May 2, 2024

FORM 6 - K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

Source: marketscreener.com
Related Topics:
United StatesDoron KerbelKiryat AryeAdi SfadiaPetah TikvaPetach TikvaKost Forer Gabbay KasiererGilat Satellite NetworksCounsel CompanyGilat Satellite Networks LtdSecurities ExchangeForeign IssuerSecurities Exchange ActYegia Kapayim StreetPrincipal Corporate OfficesAnnual General MeetingProxy StatementChief Executive OfficerKost Forer GabbayYoung Global